Yuan Jing, Liu Xuan, Wang Zhenzhen, Li Liyuan, Wang Fuxu
Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.
J Inflamm Res. 2023 Sep 18;16:4117-4121. doi: 10.2147/JIR.S428977. eCollection 2023.
Concurrent polycythemia vera with newly diagnosed multiple myeloma is extremely rare. We described a 70-year-old woman with concurrent polycythemia vera and newly diagnosed multiple myeloma. Genetic testing confirmed the JAK2 V617F mutation for the first time, while determination of serum erythropoietin decreased. A retrospective review of our patient's case was conducted thereafter, and related literature was systemically reviewed. We totally identified eight cases with concurrent polycythemia vera with newly diagnosed multiple myeloma, which were further analyzed and compared. The present case is the first patient of newly diagnosed multiple myeloma with diagnosis of polycythemia vera confirmed by positive JAK2 V617F mutation. Abnormal erythremia, hepatosplenomegaly and thrombosis history suggested comorbidity of polycythemia vera with newly diagnosed multiple myeloma. The bortezomib-based chemotherapy regimen seemed to be effective on controlling the proliferation of erythrocyte. Whereas the pathogenesis of these two entities remains to be further investigated.
真性红细胞增多症与新诊断的多发性骨髓瘤同时存在极为罕见。我们描述了一名70岁同时患有真性红细胞增多症和新诊断的多发性骨髓瘤的女性。基因检测首次证实了JAK2 V617F突变，而血清促红细胞生成素测定值降低。此后对我们患者的病例进行了回顾性分析，并对相关文献进行了系统回顾。我们共识别出8例同时患有真性红细胞增多症和新诊断的多发性骨髓瘤的病例，并对其进行了进一步分析和比较。本病例是首例经JAK2 V617F突变阳性确诊为真性红细胞增多症的新诊断多发性骨髓瘤患者。异常红细胞增多、肝脾肿大和血栓形成史提示真性红细胞增多症与新诊断的多发性骨髓瘤合并存在。基于硼替佐米的化疗方案似乎对控制红细胞增殖有效。而这两种疾病的发病机制仍有待进一步研究。
